Miocamycin。综述了其抗菌活性、药代动力学特性和治疗潜力。
文章的细节
-
引用
复制到剪贴板 -
霍利迪SM, Faulds D
Miocamycin。综述了其抗菌活性、药代动力学特性和治疗潜力。
药物。1993年10月;46(4):720-45。doi: 10.2165 / 00003495-199346040-00008。
- PubMed ID
-
7506653 (PubMed视图］
- 摘要
-
米卡霉素是一种口服的16元大环内酯类抗菌药物。它具有与红霉素类似的体外活性谱，抑制一系列革兰氏阳性和革兰氏阴性微生物、非典型微生物和一些厌氧菌。重要的是，米奥霉素在体外对包括嗜肺军团菌、人支原体和解脲支原体在内的几种病原体表现出比红霉素更强的效力。同样值得注意的是它对红霉素耐药葡萄球菌和表达诱导型耐药的链球菌的活性。米卡霉素对流感嗜血杆菌的整体活性较差，对肠杆菌科无活性。米卡霉素在人体组织和体液中的渗透既迅速又广泛。米卡霉素的3种主要代谢产物具有抗菌活性，可能有助于药物的治疗效果。临床资料表明，米卡霉素可用于治疗成人和儿科患者的上呼吸道和下呼吸道感染。米奥霉素也有效治疗由沙眼衣原体或解脲原体引起的泌尿生殖道感染。一些研究表明，在这些适应症中，米卡霉素至少与红霉素一样有效; however, comparisons with newer macrolide agents have yet to be performed. In other studies, miocamycin proved to be a useful agent in the treatment of periodontal infections and as anti-infective prophylaxis in dental surgery. Miocamycin appears to have a tolerability profile qualitatively similar to that of other macrolides, with gastrointestinal and skin disorders being the most commonly reported adverse events. Current data suggest that the potential for drug interactions with miocamycin is low, with the possible exceptions of carbamazepine and cyclosporin. Thus, although further confirmation and elaboration of various aspects of its efficacy and tolerability profile is needed, at this stage miocamycin offers a useful alternative oral therapy to erythromycin for the treatment of uncomplicated community-acquired respiratory tract infections and nongonococcal urethritis.
引用本文的药物库数据
- 药物